Post-licensure safety surveillance for human papillomavirus-16/18-AS04-adjuvanted vaccine: more than 4 years of experience

PURPOSE: To summarise post-licensure safety surveillance over more than 4 years of routine use of the human papillomavirus-16/18-AS04-adjuvanted vaccine (HPV-16/18 vaccine: Cervarix®, GlaxoSmithKline, Belgium). METHODS: We describe global post-licensure passive surveillance data based on routine pha...

Descripción completa

Detalles Bibliográficos
Autores principales: Angelo, Maria-Genalin, Zima, Julia, Tavares Da Silva, Fernanda, Baril, Laurence, Arellano, Felix
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265196/
https://www.ncbi.nlm.nih.gov/pubmed/24644078
http://dx.doi.org/10.1002/pds.3593

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265196/
https://www.ncbi.nlm.nih.gov/pubmed/24644078
http://dx.doi.org/10.1002/pds.3593

Ejemplares similares